GSA Capital Partners LLP Makes New Investment in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

GSA Capital Partners LLP purchased a new stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) in the third quarter, HoldingsChannel.com reports. The firm purchased 10,729 shares of the company’s stock, valued at approximately $268,000.

A number of other institutional investors also recently bought and sold shares of the stock. CWM LLC raised its stake in Kiniksa Pharmaceuticals by 443.0% in the 3rd quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $61,000 after acquiring an additional 1,998 shares during the last quarter. Lazard Asset Management LLC purchased a new position in shares of Kiniksa Pharmaceuticals in the first quarter worth about $71,000. nVerses Capital LLC acquired a new stake in shares of Kiniksa Pharmaceuticals during the third quarter worth about $80,000. Ashton Thomas Private Wealth LLC purchased a new stake in Kiniksa Pharmaceuticals in the second quarter valued at approximately $100,000. Finally, Lynx1 Capital Management LP acquired a new stake in shares of Kiniksa Pharmaceuticals in the second quarter worth $177,000. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

KNSA has been the subject of a number of research reports. Jefferies Financial Group started coverage on shares of Kiniksa Pharmaceuticals in a research report on Friday, September 13th. They set a “buy” rating and a $40.00 target price for the company. Evercore ISI boosted their price objective on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $36.60.

Insider Buying and Selling at Kiniksa Pharmaceuticals

In related news, COO Eben Tessari sold 17,500 shares of the company’s stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $24.99, for a total transaction of $437,325.00. Following the transaction, the chief operating officer now owns 116,975 shares of the company’s stock, valued at $2,923,205.25. This represents a 13.01 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider John F. Paolini sold 60,692 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $26.12, for a total transaction of $1,585,275.04. Following the completion of the sale, the insider now owns 52,038 shares of the company’s stock, valued at $1,359,232.56. This trade represents a 53.84 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 112,692 shares of company stock worth $2,950,315. 54.57% of the stock is currently owned by insiders.

Kiniksa Pharmaceuticals Price Performance

KNSA opened at $21.28 on Friday. The stock has a market capitalization of $1.54 billion, a price-to-earnings ratio of -152.00 and a beta of 0.35. The business has a fifty day moving average price of $24.29 and a 200 day moving average price of $22.88. Kiniksa Pharmaceuticals, Ltd. has a 12 month low of $15.52 and a 12 month high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, October 29th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.17). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business had revenue of $112.21 million during the quarter, compared to analyst estimates of $111.51 million. During the same period last year, the company earned ($0.20) earnings per share. The business’s revenue for the quarter was up 67.4% compared to the same quarter last year. On average, research analysts anticipate that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current year.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.